Biliary Tract Cancer Clinical Trials

18 studies are recruiting for biliary tract cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

  1. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCLA ( Site 0317), Los Angeles, California
    Locations
    55 in total
    Run by
    Merck Sharp & Dohme LLC
  2. Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

    The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local reg…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AdventHealth Hematology and Oncology, Orlando, Florida
    Locations
    185 in total
    Run by
    Jazz Pharmaceuticals
  3. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Alabama Birmingham, Birmingham, Alabama
    Locations
    26 in total
    Run by
    SystImmune Inc.
  4. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hoag Family Cancer Institute, Newport Beach, California
    Locations
    14 in total
    Run by
    NextCure, Inc.
  5. A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

    The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Phoenix, Arizona
    Locations
    177 in total
    Run by
    AstraZeneca
  6. Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

    The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Research Site, Scottsdale, Arizona
    Locations
    269 in total
    Run by
    AstraZeneca
  7. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage
    Phase 2
    Ages
    18 to 130
    Site
    Research Site, Los Angeles, California
    Locations
    96 in total
    Run by
    AstraZeneca
  8. AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

    The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Research Site, Orange, California
    Locations
    52 in total
    Run by
    AstraZeneca
  9. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Denver, Colorado
    Locations
    6 in total
    Run by
    ModeX Therapeutics, An OPKO Health Company
  10. Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

    The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinat…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Beverly Hills Cancer Center, Beverly Hills, California
    Locations
    12 in total
    Run by
    Replimune, Inc.
  11. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Locations
    3 in total
    Run by
    Zumutor Biologics Inc.
  12. Ligufalimab and Cadonilimab in Advanced Liver Cancers

    The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  13. Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

    Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatme…

    Stage
    Not phased
    Ages
    18 to 99
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Run by
    Cedars-Sinai Medical Center
  14. Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

    Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working. The treatment for patients whose advanced BTC either did not make the cancer better or is no longer working is a combina…

    Stage
    Phase 2
    Ages
    19 and older
    Site
    University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
    Locations
    2 in total
    Run by
    Case Comprehensive Cancer Center
  15. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Southern California, Los Angeles, California
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.
  16. Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

    This study is being done to see if the investigators can improve the outcome of patients with biliary tract cancer that do not qualify for surgery. This study will compare the effects, good and/or bad, of using a combination of standard of care chemoimmunotherapy, with the addition of radiation and…

    Stage
    Phase 1
    Ages
    21 and older
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    2 in total
    Run by
    University of Maryland, Baltimore
  17. Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

    This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered "Research" and participation is voluntary. Upon enrollment in this study, the r…

    Stage
    Not phased
    Ages
    18 to 89
    Site
    AHN West Penn Hospital, Pittsburgh, Pennsylvania
    Run by
    Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
  18. Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

    This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    CHA University Bundang Medical Center, Seongnam,
    Locations
    11 in total
    Run by
    TiumBio Co., Ltd.

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.